1-3 of 3
Genmin Lu
Close
Sort by
Journal Articles

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

Clinical Trials & Observations
Genmin Lu, Pamela B. Conley, Janet M. Leeds, Mark J. Karbarz, Gallia G. Levy, Vandana S. Mathur, Janice Castillo, Mark Crowther, John T. Curnutte
Journal: Blood Advances
Blood Adv (2020) 4 (4): 728–739.
https://doi.org/10.1182/bloodadvances.2019000885
Published: 2020
Includes: Supplemental data
Journal Articles

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

Manu T. Kalathottukaren, A. Louise Creagh, Srinivas Abbina, Genmin Lu, Mark J. Karbarz, Anjali Pandey, Pamela B. Conley, Jayachandran N. Kizhakkedathu, Charles Haynes
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2104–2114.
https://doi.org/10.1182/bloodadvances.2016003616
Published: 2018
Includes: Supplemental data
Journal Articles

Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa

Deborah Siegal, Genmin Lu, Janet M. Leeds, Mark Karbarz, Janice Castillo, Vandana Mathur, Athiwat Hutchaleelaha, Uma Sinha, Michael Kitt, Matt McClure, Stanley J. Hollenbach, John T. Curnutte, Pamela B. Conley, Mark Crowther
Journal: Blood Advances
Blood Adv (2017) 1 (21): 1827–1838.
https://doi.org/10.1182/bloodadvances.2017007112
Published: 2017
Includes: Supplemental data